healthcare
FinanceMedical Products Maker Convatec Rises After Robust 2026 Outlook on Growing Demand
New, Effective Anti-Malaria Drug Could Help Fight Rising Resistance, Says Novartis
WeightWatchers to Offer Novo Nordisk's Wegovy Pill After 2026 Launch
InvestingUnderstanding the Global Impact of Rising Medical Insurance Premiums on the Middle Class
Gaza Patients Face a Painful Wait as Hospitals Sag Under Burden of Cases
Date: November 12, 2025
By Nidal al-Mughrabi CAIRO/GAZA (Reuters) -Fourteen-year-old Mohammed Wael Helles has been waiting for surgery on a serious spinal injury caused by an Israeli airstrike for nearly two months, one of...
Novartis Opens New Plant in California to Make Cancer Drugs
Date: November 10, 2025
By Patrick Wingrove (Reuters) -Swiss drugmaker Novartis said on Monday it has opened a new 10,000-square-foot factory in Carlsbad, California, to make cancer treatments, as part of its pledge to...
Eli Lilly Signs Deal for MeiraGTx's Gene Therapy for Severe Eye Disease
Date: November 10, 2025
(Reuters) -MeiraGTx Holdings has signed a deal with Eli Lilly, potentially worth over $475 million, granting the pharma giant rights to its experimental gene therapy for a rare, inherited disorder...
Novo Nordisk, Emcure to Launch Weight-Loss Drug Under New Brand in India
Date: November 10, 2025
(Reuters) -Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market weight-loss drug Poviztra semaglutide injection in the country, the Indian firm said on...
Novo Nordisk Expects Negative Low Single-Digit Impact on Global Sales Growth in 2026 (Nov 6)
Date: November 6, 2025
(Reuters) -Novo Nordisk expects global sales to decline by low-single-digit percentage in 2026 after the drugmaker unveiled a deal on Thursday to slash prices of popular GLP-1 weight‑loss drugs for...
AstraZeneca Holds Forecasts as Cancer, Heart Drugs Lift Earnings
Date: November 6, 2025
(Reuters) -AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of key cancer, heart and kidney disease drugs, prompting London's most valuable listed company to...